Last reviewed · How we verify
RSD1235
RSD1235 is a potassium channel opener that suppresses atrial fibrillation by prolonging atrial refractoriness and reducing atrial conduction velocity.
RSD1235 is a potassium channel opener that suppresses atrial fibrillation by prolonging atrial refractoriness and reducing atrial conduction velocity. Used for Atrial fibrillation (acute conversion and prevention of recurrence).
At a glance
| Generic name | RSD1235 |
|---|---|
| Also known as | vernakalant, Kynapid |
| Sponsor | Astellas Pharma Inc |
| Drug class | Potassium channel opener |
| Target | ATP-sensitive potassium channels (KATP) |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
RSD1235 works by opening ATP-sensitive potassium channels in atrial tissue, which hyperpolarizes cardiac myocytes and increases the refractory period. This electrophysiological effect reduces the ability of ectopic foci to trigger arrhythmias and slows conduction, thereby terminating or preventing atrial fibrillation episodes. The drug's selective action on atrial tissue aims to minimize ventricular side effects.
Approved indications
- Atrial fibrillation (acute conversion and prevention of recurrence)
Common side effects
- Hypotension
- Bradycardia
- Headache
- Dizziness
Key clinical trials
- RAFF4 Trial: Vernakalant vs. Procainamide for Acute Atrial Fibrillation in the Emergency Department (PHASE4)
- Vernakalant Versus Amiodarone for Post-operative Atrial Fibrillation in Cardiac Surgery Patients (PHASE3)
- Predictive Factors to Effectively Terminate Paroxysmal Atrial Fibrillation by Blocking Atrial Selective Ionic Currents (PHASE4)
- Study of Normal Conditions of Use, Dosing, and Safety of Intravenous (IV) Administration of Vernakalant (MK-6621-049)
- A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4) (PHASE3)
- Vernakalant Versus Ibutilide In Recent-Onset Atrial Fibrillation (PHASE4)
- A Phase 3b Study of Vernakalant Injection in Patients With Recent Onset Symptomatic Atrial Fibrillation (AF)(MK-6621-045) (PHASE3)
- A Study Comparing Vernakalant Therapy to Amiodarone Therapy in Acute Management of Recent Onset Atrial Fibrillation (AF) (MK-6621-055) (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RSD1235 CI brief — competitive landscape report
- RSD1235 updates RSS · CI watch RSS
- Astellas Pharma Inc portfolio CI